Key Metrics
CiteScore 

9.8
Eigenfactor 

0.005 - 0.01
Impact Factor 

5 - 10
SJR 

Q1Neurology (clinical)

SNIP 

1.87
Recommended pre-submission checks
Powered by 

Topics Covered on CNS Drugs
CNS Drugs Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
SJR
| Overview | |
| Publisher | ADIS INT LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1994 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in CNS Drugs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in CNS Drugs
Multiple Sclerosis in Women: Impact of Different Life Stages on Treatment Decisions.
- 1 Mar 2026
- CNS drugs
Zolpidem May Affect Glial Flow in Addition to Norepinephrine-Mediated Vasomotility of the Glymphatic System.
- 1 Mar 2026
- CNS drugs
Correction: Evaluation of Safety, Pharmacokinetic, and Pharmacodynamic Characteristics of a Novel Dual mGluR5/5‑HT2AR Antagonist (VVZ‑2471) in a Randomized, Double‑Blind, First‑in‑Human Study.
- 26 Feb 2026
- CNS drugs
Efficacy and Safety of Cannabinoids for Neuropsychiatric Symptoms of Dementia: A Systematic Review with Meta-analysis
- 26 Feb 2026
- CNS Drugs
TRPV1 Receptor Modulators: Emerging Therapies for Neuropathic, Osteoarthritic, and Perioperative Pain.
- 21 Feb 2026
- CNS drugs
Ameliorating Seizures in Dravet Syndrome: A Review of Newly Approved and Investigational Drugs, RNA and Gene-Based Therapies.
- 19 Feb 2026
- CNS drugs
Multiple Sclerosis in Women: Impact of Different Life Stages on Treatment Decisions.
- 1 Mar 2026
- CNS drugs
Zolpidem May Affect Glial Flow in Addition to Norepinephrine-Mediated Vasomotility of the Glymphatic System.
- 1 Mar 2026
- CNS drugs
Correction: Evaluation of Safety, Pharmacokinetic, and Pharmacodynamic Characteristics of a Novel Dual mGluR5/5‑HT2AR Antagonist (VVZ‑2471) in a Randomized, Double‑Blind, First‑in‑Human Study.
- 26 Feb 2026
- CNS drugs
Efficacy and Safety of Cannabinoids for Neuropsychiatric Symptoms of Dementia: A Systematic Review with Meta-analysis
- 26 Feb 2026
- CNS Drugs
TRPV1 Receptor Modulators: Emerging Therapies for Neuropathic, Osteoarthritic, and Perioperative Pain.
- 21 Feb 2026
- CNS drugs
Ameliorating Seizures in Dravet Syndrome: A Review of Newly Approved and Investigational Drugs, RNA and Gene-Based Therapies.
- 19 Feb 2026
- CNS drugs
FAQs on CNS Drugs
How long has CNS Drugs been actively publishing? 
What is the publishing frequency of CNS Drugs? 
How many articles did CNS Drugs publish last year? 
What is the eISSN & pISSN for CNS Drugs? 
What is Citescore for CNS Drugs? 
What is SNIP score for CNS Drugs? 
What is the SJR for CNS Drugs? 
Who is the publisher of CNS Drugs? 
Check if your manuscript is a good match for
undefined
Upload your manuscript to get recommendations of journals
that have published papers similar to your manuscript
Drag and drop your file here
We accept manuscripts in English. File format: .doc and .docx | Maximum size: 10 MB | Word count: 200-300,000 words | File length: less than 100 pages
Do not have a manuscript right now? Use an abstract or summary